Vaccination of mice with a modified Vaccinia Ankara (MVA) virus expressing the African horse sickness virus (AHSV) capsid protein VP2 induces virus neutralising antibodies that confer protection against AHSV upon passive immunisation

Virus Research

Volumn 180, Issue , 2014, Pages 23-30

  Calvo Pinilla, Eva ^a   de la Poza, Francisco ^b   Gubbins, Simon ^a   Mertens, Peter Paul Clement ^a   Ortego, Javier ^b   Castillo Olivares, Javier ^a  

^a INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

^b Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria Consejo Superior de Investigaciones Científicas   (Spain)

Author keywords

African horse sickness; Humoral response; MVA VP2; Passive immunisation; Protection; Vaccinia

Indexed keywords

MVA VP2 VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VACCINIA VACCINE;

AFRICAN HORSE SICKNESS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DONOR; EMBRYO; HUMORAL IMMUNITY; INFECTION PREVENTION; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; RECIPIENT; WILD TYPE;

AFRICAN HORSE SICKNESS; HUMORAL RESPONSE; MVA-VP2; PASSIVE IMMUNISATION; PROTECTION; VACCINIA;

AFRICAN HORSE SICKNESS; AFRICAN HORSE SICKNESS VIRUS; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CAPSID PROTEINS; DISEASE MODELS, ANIMAL; DRUG CARRIERS; IMMUNIZATION, PASSIVE; MICE; MICE, KNOCKOUT; VACCINIA VIRUS; VIRAL VACCINES; VIREMIA;

EID: 84893013132     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2013.12.002     Document Type: Article

References (25)

1. Belhouchet M., Mohd Jaafar F., Firth A.E., Grimes J.M., Mertens P.P., Attoui H. Detection of a fourth orbivirus non-structural protein. PloS One 2011, 6:e25697.
2. Bentley L., Fehrsen J., Jordaan F., Huismans H., du Plessis D.H. Identification of antigenic regions on VP2 of African horsesickness virus serotype 3 by using phage-displayed epitope libraries. The Journal of General Virology 2000, 81:993-1000.
3. Blackburn N.K., Swanepoel R. Observations on antibody levels associated with active and passive immunity to African horse sickness. Tropical Animal Health and Production 1988, 20:203-210.
4. Burrage T.G., Trevejo R., Stone-Marschat M., Laegreid W.W. Neutralizing epitopes of African horsesickness virus serotype 4 are located on VP2. Virology 1993, 196:799-803.
5. Calvo-Pinilla E., Navasa N., Anguita J., Ortego J. Multiserotype protection elicited by a combinatorial prime-boost vaccination strategy against bluetongue virus. PLoS One 2012, 7:e34735.
6. Calvo-Pinilla E., Rodriguez-Calvo T., Anguita J., Sevilla N., Ortego J. Establishment of a bluetongue virus infection model in mice that are deficient in the alpha/beta interferon receptor. PLoS One 2009, 4:e5171.
7. Castillo-Olivares J., Calvo-Pinilla E., Casanova I., Bachanek-Bankowska K., Chiam R., Maan S., Nieto J.M., Ortego J., Mertens P.P. A modified Vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR-/- mouse model. PloS One 2011, 6:e16503.
8. Chiam R., Sharp E., Maan S., Rao S., Mertens P., Blacklaws B., Davis-Poynter N., Wood J., Castillo-Olivares J. Induction of antibody responses to African horse sickness virus (AHSV) in ponies after vaccination with recombinant modified Vaccinia Ankara (MVA). PloS One 2009, 4:e5997.
9. de la Poza F., Calvo-Pinilla E., López-Gil E., Marín-López A., Mateos F., Castillo-Olivares J., Lorenzo G., Ortego J. NS1 is a key protein in the vaccine composition to protect IFNAR(-/-) mice against infection with multiple serotypes of African horse sickness virus. PLoS One 2013, 8:e70197.
10. El Garch H., Crafford J.E., Amouyal P., Durand P.Y., Edlund Toulemonde C., Lemaitre L., Cozette V., Guthrie A., Minke J.M. An African horse sickness virus serotype 4 recombinant canarypox virus vaccine elicits specific cell-mediated immune responses in horses. Veterinary immunology and immunopathology 2012, 149:76-85.
11. Guthrie A.J., Quan M., Lourens C.W., Audonnet J.C., Minke J.M., Yao J., He L., Nordgren R., Gardner I.A., Maclachlan N.J. Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus. Vaccine 2009, 27:4434-4438.
12. House J.A., Lombard M., Dubourget P., House C., Mebus C.A. Further studies on the efficacy of an inactivated African horse sickness serotype 4 vaccine. Vaccine 1994, 12:142-144.
13. Karber G. 50% end-point calculation. Archiv fur Experimentalle Pathologie und Pharmakologie 1931, 162:480-483.
14. Manole V., Laurinmaki P., Van Wyngaardt W., Potgieter C.A., Wright I.M., Venter G.J., van Dijk A.A., Sewell B.T., Butcher S.J. Structural insight into African horsesickness virus infection. Journal of Virology 2012, 86:7858-7866.
15. Martinez-Torrecuadrada J.L., Casal J.I. Identification of a linear neutralization domain in the protein VP2 of African horse sickness virus. Virology 1995, 210:391-399.
16. Martinez-Torrecuadrada J.L., Diaz-Laviada M., Roy P., Sanchez C., Vela C., Sanchez-Vizcaino J.M., Casal J.I. Full protection against African horsesickness (AHS) in horses induced by baculovirus-derived AHS virus serotype 4 VP2, VP5 and VP7. The Journal of General Virology 1996, 77(Pt 6):1211-1221.
17. Mellor P.S., Hamblin C. African horse sickness. Veterinary Research 2004, 35:445-466.
18. Ozawa Y., Bahrami S. African horse-sickness killed-virus tissue culture vaccine. Canadian Journal of Comparative Medicine and Veterinary Science 1966, 30:311-314.
19. Pretorius A., Van Kleef M., Van Wyngaardt W., Heath J. Virus-specific CD8(+) T-cells detected in PBMC from horses vaccinated against African horse sickness virus. Veterinary immunology and immunopathology 2012, 146:81-86.
20. R-Core-Team R. A Language and Environment for Statistical Computing 2012, R Foundation for Statistical Computing, Austria, Viena.
21. Romito M., Du Plessis D.H., Viljoen G.J. Immune responses in a horse inoculated with the VP2 gene of African horsesickness virus. Onderstepoort Journal of Veterinary Research 1999, 66:139-144.
22. Roy P., Bishop D.H., Howard S., Aitchison H., Erasmus B. Recombinant baculovirus-synthesized African horsesickness virus (AHSV) outer-capsid protein VP2 provides protection against virulent AHSV challenge. Journal of General Virology 1996, 77(Pt 9):2053-2057.
23. Roy P., Mertens P.P., Casal I. African horse sickness virus structure. Comparative Immunology Microbiology and Infectious Diseases 1994, 17:243-273.
24. Stone-Marschat M.A., Moss S.R., Burrage T.G., Barber M.L., Roy P., Laegreid W.W. Immunization with VP2 is sufficient for protection against lethal challenge with African horsesickness virus Type 4. Virology 1996, 220:219-222.
25. van Staden V., Theron J., Greyling B.J., Huismans H., Nel L.H. A comparison of the nucleotide sequences of cognate NS2 genes of three different orbiviruses. Virology 1991, 185:500-504.